New drug approach offers hope for patients with recurrent aggressive cancers

A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial.

Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met its "primary endpoints" of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.

The TroFuse-005 trial is the first global Phase 3 trial to "demonstrate statistically significant improvement" in survival compared to chemotherapy in these patients, according to a Merck press release.